Chinese biophysicist Rao Zhihe has been appointed the first strategic scientist at a new innovation hub, signaling a deepening collaboration between China and Thailand in health and life sciences. This partnership brings together "industry and university leaders" to discuss biomedical research, laying groundwork for future market expansion in a sector ripe for capital accumulation. Rao, a professor at Tsinghua and ShanghaiTech universities, recently made his first trip abroad in three years for an interview in Bangkok last month, underscoring the strategic importance of these new alliances.
Rao has been working on natural anti-Covid products with Mahidol University researchers. Early in the coronavirus pandemic, his team identified two parts of the virus that could be targeted by drugs. This information was shared with over 300 universities, research institutes, and companies before the findings were published, a temporary deviation from the typical enclosure of intellectual property that defines the pharmaceutical industry. He stated this sharing aimed to speed up the development of effective drugs, a process that ultimately yields immense profits for those companies.
Forging New Markets
The Association of Pacific Rim Universities organized a forum where these collaborations were discussed. The forum explicitly gathered "industry and university leaders" to explore how "biomedical research partnerships" across the Asia-Pacific region could prevent future pandemics. This framing positions scientific cooperation as a vehicle for corporate interests, securing access to research, talent, and ultimately, new markets for health products. Rao himself noted, "I believe China and Thailand have good room for cooperation," a statement that can be read as an invitation for further capital investment and market integration.
The "innovation hub" itself represents a state-backed initiative to facilitate these partnerships. Such hubs often serve to streamline the flow of research from public institutions into private hands, accelerating the commodification of health solutions. While the stated goal is pandemic prevention, the mechanism involves "industry leaders," whose primary directive is profit generation.
The Promise of Profit
Rao emphasized the world's "desperate" need for a broad-spectrum and effective antiviral drug for ongoing and future coronavirus pandemics. He stated his team was working towards this goal, stressing that "joint efforts from international scientists were key." This focus on drug development, while presented as a humanitarian necessity, aligns perfectly with the profit motive of the pharmaceutical industry. The "desperate need" creates a guaranteed market for any successful product, ensuring substantial returns for the "companies" involved in the research and development pipeline. The sharing of information, while seemingly altruistic, ultimately feeds into a system designed to produce and sell commodities.
The collaboration, therefore, isn't merely about scientific advancement. It's about establishing frameworks for capital to penetrate new territories and secure future revenue streams from global health crises. The "innovation hub" acts as a conduit, channeling public and academic resources towards outcomes that benefit private capital.